Autoimmune syndromes presenting as a paraneoplastic manifestation of myelodysplastic syndromes: clinical features, course, treatment and outcome

Bradley T. Williamson, 1, Lynda Foltz, 2 Heather A. Leitch 2
Departments of Medicine and 2Hematology, St. Paul’s Hospital and the University of British Columbia, Vancouver, BC, Canada

Abstract

Autoimmune manifestations (AIM) are reported in up to 10-30% of myelodysplastic syndromes (MDS) patients; this association is not well defined. We present herein a retrospective chart review of single center MDS patients for AIM, a case discussion and a literature review. Of 252 MDS patients examined, 11 (4.4%) had AIM around MDS diagnosis. International Prognostic Scoring System scores were: low or intermediate (int)-1 (n=7); int-2 or high (n=4). AIM were: culture negative sepsis (n=7); inflammatory arthritis (n=3); vasculitis (n=4); sweaty; pericarditis; polymyalgia rheumatica (n=2 each); mouth ulcers; pulmonary infiltrates; suspicion for Behcet’s; polychondritis and undifferentiated (n=1 each). AIM treatment and outcome were: prednisone +/- steroid sparing agents, n=8, ongoing symptoms in 5; azacitidine (n=3), 2 resolved; and observation, n=1, ongoing symptoms. At a median follow up of 13 months, seven patients are alive. In summary, 4.4% of MDS patients presented with concomitant AIM. MDS should remain on the differential diagnosis of patients with inflammatory symptoms.

Introduction

The myelodysplastic syndromes (MDS) are clonal hematopoietic disorders of ineffective hematopoiesis and risk of acute myeloid leukemia (AML) progression.1 Prognosis is determined by the International Prognostic Scoring System (IPSS) and other scores.2 Mutations in the pluripotent hematopoietic stem cell occur in MDS, with disruption of RNA splicing, ribosomal proteins, telomeres, microRNA expression, and DNA methylation.3 4 Reports suggest an association between MDS and immune dysregulation.5 Cytokine dysregulation and impaired cellular immunity have been noted in MDS initiation, development, and progression.6 Autoimmune (AI) symptoms have been reported in up to 10-30% of MDS patients.3 7 8 Patients with AI disorders or receiving immunosuppressive agents are more likely to be diagnosed with MDS.9 10

Paraneoplastic inflammatory syndromes concomitant with MDS diagnosis have also been reported.3 11 12 To better understand the incidence and outcomes of patients with MDS and AI disorders, we conducted a retrospective chart review of patients with MDS, looking for symptoms of AI disorders.

Materials and Methods

Myelodysplastic syndromes patients were identified from a single-center MDS database. Charts were reviewed for the presence of autoimmune manifestations (AIM) within a 3-year period prior to or following the diagnosis of MDS, treatment and outcome. Patients with a longstanding history of connective tissue disorders were excluded. The term culture negative sepsis was used to describe fevers or drenching sweats with a negative workup for infectious and other causes such as drug fevers. Although these symptoms may be a manifestation of systemic vasculitis, the latter term was reserved for patients with biopsy-proven vasculitis. Cases that are illustrative of AIM were selected for presentation.

Survival analyses were conducted by the log-rank method using SPSS for Windows, version 20. This review was conducted in accordance with the requirements of the institutional Research Ethics Board.

Results

Of 252 MDS patients, eleven (4.4%) had AIM presenting at or shortly before MDS diagnosis. Baseline and MDS characteristics, treatment and outcome are shown in Table 1. Eight patients were documented to have had a workup by the rheumatology service, and seven were followed regularly by the rheumatology service, and one underwent CT scanning of the abdomen because of abdominal pain; the spleen was normal on imaging.

At a median follow up of 13 (4-87) months, seven patients are still alive, six with stable MDS and one is undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Four patients died; causes were: MDS progression, n=2; infection, n=1; and unknown, n=1.

Of four patients with int-2 or high IPSS risk MDS, three were treated with azacitidine. One patient receiving azacitidine did not respond, and there was one early infectious death, and the third is undergoing HSCT.

Overall survival (OS) analyses were performed comparing MDS patients with AIM to those without AIM. The OS of seven lower IPSS risk patients with AIM were compared to 204 lower risk MDS diagnosed over the same time period of more than 7 years. Two patients had ferritin levels done; the maximum level was 1200 ng/mL. None of the patients had splenomegaly on physical examination, and one underwent CT scanning of the abdomen because of abdominal pain; the spleen was normal on imaging.

Hematology Reports 2016; volume 8:6480

Correspondence: Heather A. Leitch, St. Paul’s Hospital and the University of British Columbia, 440-1144 Burrard Street, Vancouver V6E 2A5, BC, Canada.
Tel.: +1.604.684.5794 - Fax: +1.604.684.5705.
E-mail: hleitch@providencehematology.com

Key words: Autoimmune; myelodysplastic syndromes; HDS.

Conflict of interest: BTW reviewed the charts and wrote the paper; LMF critically revised the paper; HAL, supervised the chart review, revised the paper and performed statistical analyses.

Materials and Methods

MDS, two received immunosuppressive agents are more likely to be diagnosed with MDS.12

Paraneoplastic inflammatory syndromes concomitant with MDS diagnosis have also been reported.3 11 12 To better understand the incidence and outcomes of patients with MDS and AI disorders, we conducted a retrospective chart review of patients with MDS, looking for symptoms of AI disorders.

Survival analyses were conducted by the log-rank method using SPSS for Windows, version 20. This review was conducted in accordance with the requirements of the institutional Research Ethics Board.

Results

Of 252 MDS patients, eleven (4.4%) had AIM presenting at or shortly before MDS diagnosis. Baseline and MDS characteristics, treatment and outcome are shown in Table 1. Eight patients were documented to have had a workup by the rheumatology service, and seven were followed regularly by the rheumatology service, and one underwent CT scanning of the abdomen because of abdominal pain; the spleen was normal on imaging.

At a median follow up of 13 (4-87) months, seven patients are still alive, six with stable MDS and one is undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Four patients died; causes were: MDS progression, n=2; infection, n=1; and unknown, n=1.

Of four patients with int-2 or high IPSS risk MDS, three were treated with azacitidine. One patient receiving azacitidine did not respond, and there was one early infectious death, and the third is undergoing HSCT.

Overall survival (OS) analyses were performed comparing MDS patients with AIM to those without AIM. The OS of seven lower IPSS risk patients with AIM were compared to 204 lower risk MDS diagnosed over the same time period of more than 7 years. Two patients had ferritin levels done; the maximum level was 1200 ng/mL. None of the patients had splenomegaly on physical examination, and one underwent CT scanning of the abdomen because of abdominal pain; the spleen was normal on imaging.

At a median follow up of 13 (4-87) months, seven patients are still alive, six with stable MDS and one is undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Four patients died; causes were: MDS progression, n=2; infection, n=1; and unknown, n=1.

Of four patients with int-2 or high IPSS risk MDS, three were treated with azacitidine. One patient receiving azacitidine did not respond, and there was one early infectious death, and the third is undergoing HSCT.

Overall survival (OS) analyses were performed comparing MDS patients with AIM to those without AIM. The OS of seven lower IPSS risk patients with AIM were compared to 204 lower risk MDS diagnosed over the same time period of more than 7 years. Two patients had ferritin levels done; the maximum level was 1200 ng/mL. None of the patients had splenomegaly on physical examination, and one underwent CT scanning of the abdomen because of abdominal pain; the spleen was normal on imaging.

At a median follow up of 13 (4-87) months, seven patients are still alive, six with stable MDS and one is undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Four patients died; causes were: MDS progression, n=2; infection, n=1; and unknown, n=1.

Of four patients with int-2 or high IPSS risk MDS, three were treated with azacitidine. One patient receiving azacitidine did not respond, and there was one early infectious death, and the third is undergoing HSCT.

Overall survival (OS) analyses were performed comparing MDS patients with AIM to those without AIM. The OS of seven lower IPSS risk patients with AIM were compared to 204 lower risk MDS diagnosed over the same time period of more than 7 years. Two patients had ferritin levels done; the maximum level was 1200 ng/mL. None of the patients had splenomegaly on physical examination, and one underwent CT scanning of the abdomen because of abdominal pain; the spleen was normal on imaging.

At a median follow up of 13 (4-87) months, seven patients are still alive, six with stable MDS and one is undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Four patients died; causes were: MDS progression, n=2; infection, n=1; and unknown, n=1.

Of four patients with int-2 or high IPSS risk MDS, three were treated with azacitidine. One patient receiving azacitidine did not respond, and there was one early infectious death, and the third is undergoing HSCT.

Overall survival (OS) analyses were performed comparing MDS patients with AIM to those without AIM. The OS of seven lower IPSS risk patients with AIM were compared to 204 lower risk MDS diagnosed over the same time period of more than 7 years. Two patients had ferritin levels done; the maximum level was 1200 ng/mL. None of the patients had splenomegaly on physical examination, and one underwent CT scanning of the abdomen because of abdominal pain; the spleen was normal on imaging.

At a median follow up of 13 (4-87) months, seven patients are still alive, six with stable MDS and one is undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Four patients died; causes were: MDS progression, n=2; infection, n=1; and unknown, n=1.

Of four patients with int-2 or high IPSS risk MDS, three were treated with azacitidine. One patient receiving azacitidine did not respond, and there was one early infectious death, and the third is undergoing HSCT.

Overall survival (OS) analyses were performed comparing MDS patients with AIM to those without AIM. The OS of seven lower IPSS risk patients with AIM were compared to 204 lower risk MDS diagnosed over the same time period of more than 7 years. Two patients had ferritin levels done; the maximum level was 1200 ng/mL. None of the patients had splenomegaly on physical examination, and one underwent CT scanning of the abdomen because of abdominal pain; the spleen was normal on imaging.

At a median follow up of 13 (4-87) months, seven patients are still alive, six with stable MDS and one is undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Four patients died; causes were: MDS progression, n=2; infection, n=1; and unknown, n=1.
period. The median follow up of all lower risk patients was 27.3 (0.5-161) months. There was no significant difference in OS between groups; all seven (100%) patients with AIM are alive compared to 166 (78.7%) patients without AIM, and the median OS was not reached at 43 months compared to 78.8 months, respectively (P=NS).

Of higher IPSS risk patients, we restricted the analysis to patients diagnosed since azacitidine was available in Canada and compared three patients with AIM receiving azacitidine to 29 patients without AIM, but also receiving azacitidine. The median follow up of this group was 7.3 (0.5-46) months. There was no significant difference in OS between groups (P=NS).

Of eight patients receiving immunosuppression for AIM, one died of AML progression at 4 months, one died of progressive (higher IPSS risk) MDS in the context of stopping azacitidine at 6 months, and one died suddenly of unknown causes 32 months from MDS diagnosis. The remaining five patients had stable MDS at a median of 14 (5-23) months from MDS diagnosis. Four of these patients were followed by Rheumatology and the fifth was given immunosuppressive medications by emergency room physicians for pericarditis.

Both patients with systemic vasculitis had this diagnosis made on biopsy, one on open lung biopsy, and one on skin biopsy. Only one patient, without biopsy proven vasculitis but with culture negative sepsis, had anti-neutrophil cytoplasmic antibody (ANCA) levels done, which were negative.

**Patient**

A 31 year-old woman presented with fatigue and cytopenias. White blood cell (WBC) count was 3.9×10^9/L, neutrophils 1.8×10^9/L, hemoglobin (Hb) 125 g/L and platelet count (PLTS) 100×10^9/L. Peripheral blood morphology showed macrocytosis. Antinuclear antibody (ANA) was positive at a 1:320 dilution. She did not fulfill criteria for systemic lupus erythematosus (SLE) and was observed. Neutropenia and thrombocytopenia persisted and mild anemia developed (Hb 119 g/L). A bone marrow aspirate and biopsy (BMBx) showed erythroid dysplasia, 1% blasts and trisomy 8. A diagnosis of refractory cytopenia with unilineage dysplasia (RCUD) was made and the IPSS was int-1. The patient declined HSCT and yearly BMBx’s remained stable. Within one year of MDS diagnosis, she developed a rash to sun exposure. She experienced culture negative fevers and mouth ulcers suspicious for Behcet’s disease. Symptoms are ongoing 9.75 years from MDS diagnosis despite the use of non-steroidal anti-inflammatory medications. AIM nearly completely abated during three pregnancies.

| Table 1. Autoimmune manifestations of myelodysplastic syndromes in 11 patients: clinical features, treatment and outcome. |
|----------------|--------------------------------------------------|
| **Characteristic** | **N (%) /Median (range)** |
| Age (years) | 68 (34-84) |
| Gender (male) | 7 (64) |
| FAB* or WHO MDS diagnosis | |
| RCUD | 2 |
| RAMD-RA | 2 |
| RA | 1 |
| RARS | 1 |
| RCMD | 1 |
| RAEB-1a | 1 |
| MDNs-NOS | 1 |
| CMML-2 | 1 |
| IPSS risk | |
| Low | 3 |
| Intermediate-1 | 4 |
| Intermediate-2 | 3 |
| High | 1 |
| IPSS cytogenetics group | |
| Good | 6 |
| Intermediate | 2 |
| Poor | 3 |
| Significant conditions | |
| No | 8 |
| Yes | 3 |
| MDS treatment | |
| Observation | 5 |
| Supportive care<sup>a</sup> | 3 |
| Azacitidine | 3 |
| MDS outcome | |
| Stable | 6 |
| Good response | 1 |
| Died<sup>a</sup> | 4 |
| Autoimmune manifestation (AIM) | |
| Culture negative sepsis | 7 |
| Inflammatory arthritis | 3 |
| Systemic vasculitis | 2 |
| Cutaneous vasculitis | 1 |
| Polymyalgia rheumatica | 2 |
| Connective tissue disorder NOS | 2 |
| Polychondritis | 1 |
| Pericarditis | 2 |
| AIM months in relation to MDS diagnosis | 1 (-38-34) |
| Serological abnormalities | |
| Positive ANA | 6 |
| Elevated CRP | 5 |
| Elevated ESR | 2 |
| Monoclonal paraprotein | 1 |
| Positive RF | 1 |
| AIM treatment | |
| Observation | 3 |
| Prednisone | <sup>8</sup> |
| Methotrexate | 4 |
| Hydroxychloroquine | 4 |
| Azathioprine | 2 |
| Gold | 1 |
| Chlorambucil | 2 |
| Dapsone | 1 |
| AIM outcome | |
| Resolution of all symptoms | 3 |
| Partial resolution of symptoms | 4 |
| Persistent symptoms | 4 |

<sup>a</sup>ANA, anti-nuclear antibody; CMML, chronic myelomonocytic leukemia; CCR, C reactive protein; EB-t, excess blasts in transformation; ESR, erythrocyte sedimentation rate; FAB, French-American-British; IPSS, International Prognostic Scoring System; MD, multilineage dysplasia; MDS, myelodysplastic syndrome; NOS, not otherwise specified; RA, refractory anemia; RS, ring sideroblasts; RF, rheumatoid factor; t-, treatment related; UD, Unilineage dysplasia. *According to era of MDS diagnosis; †MDS; ‡myasthenia gravis and systemic lupus erythematosus; psoriatic arthritis, polychondritis and vasculitis; well-controlled HIV infection; n=1 each. The course of the HIV-positive patient has been published in detail (Williamsen EF & Leitch JA, 2018). Aerythropoietin, n=2; red blood cell transfusion + iron chelation therapy, n=1. Aerythropoietin, n=2; complications of treatment, n=1; unknown cause, n=1. 7 in combination with other agents.
Patient #2

A 77 year-old man presented with fatigue. Hb was 127 g/L, neutrophils 1.8×10⁹/L, and PLTS 133×10⁹/L. ANA titer was 1:80. A BMX showed trilineage dysplasia, <5% blasts and a normal male karyotype. A diagnosis of refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS) was made and the IPSS was int-1.

Six months after MDS diagnosis he developed progressive stiffness of the thighs, shoulders and neck. Workup revealed a positive rheumatoid factor (RF), C-reactive protein (CRP) of 44.2 mg/L (>7 mg/L indicates inflammation) and erythrocyte sedimentation rate (ESR) of 34 mm/hr (upper limit of normal 10 mm/hr). He was diagnosed with rheumatoid arthritis (RA) with a polymyalgia rheumatica (PMR)-type onset. He received 40 mg prednisone daily with near complete resolution of symptoms, and was transitioned to hydroxychloroquine and methotrexate.

Patient #3

A 66 year-old man presented with drenching sweats and chest pain, the latter diagnosed as pericarditis and treated with aspirin and colchicine. One week later, he developed abdominal pain suspicious forBehcet's disease. A CBCD revealed a Hb of 110 g/L and a leukoerythroblastic picture. WBC count was 5.9×10⁹/L, neutrophils 1.1×10⁹/L, PLTS decreased (count unavailable due to clumping). A BMX showed multilineage dysplasia, ring sideroblasts, 4% blasts and a complex karyotype. A diagnosis of RCMD-RS was made and the IPSS was int-2. He was initiated on azacitidine. Four months later, he developed culture-negative sepsis, three episodes in total. He also had a widespread, recurrent petechial rash without significant thrombocytopenia. A second BMX one month after cycle two of azacitidine showed no MDS progression. He received four cycles of azacitidine and went into CR. He continues to suffer from fatigue and episodes of pericarditis; however, the other symptoms abated. He is undergoing HSCT.

Patient #4

A 39-year-old man presented with drenching sweats and chest pain, the latter diagnosed as pericarditis and treated with aspirin and colchicine. One week later, he developed abdominal pain suspicious for Behcet's disease. A CBCD revealed a Hb of 110 g/L and a leukoerythroblastic picture. WBC count was 5.9×10⁹/L, neutrophils 1.1×10⁹/L, PLTS decreased (count unavailable due to clumping). A BMX showed multilineage dysplasia, ring sideroblasts, 4% blasts and a complex karyotype. A diagnosis of RCMD-RS was made and the IPSS was int-2. He was initiated on azacitidine. Four months later, he developed culture-negative sepsis, three episodes in total. He also had a widespread, recurrent petechial rash without significant thrombocytopenia. A second BMX one month after cycle two of azacitidine showed no MDS progression. He received four cycles of azacitidine and went into CR. He continues to suffer from fatigue and episodes of pericarditis; however, the other symptoms abated. He is undergoing HSCT.

Patient #5

A 39-year-old man presented with drenching sweats and chest pain, the latter diagnosed as pericarditis and treated with aspirin and colchicine. One week later, he developed abdominal pain suspicious for Behcet's disease. A CBCD revealed a Hb of 110 g/L and a leukoerythroblastic picture. WBC count was 5.9×10⁹/L, neutrophils 1.1×10⁹/L, PLTS decreased (count unavailable due to clumping). A BMX showed multilineage dysplasia, ring sideroblasts, 4% blasts and a complex karyotype. A diagnosis of RCMD-RS was made and the IPSS was int-2. He was initiated on azacitidine. Four months later, he developed culture-negative sepsis, three episodes in total. He also had a widespread, recurrent petechial rash without significant thrombocytopenia. A second BMX one month after cycle two of azacitidine showed no MDS progression. He received four cycles of azacitidine and went into CR. He continues to suffer from fatigue and episodes of pericarditis; however, the other symptoms abated. He is undergoing HSCT.

Discussion and Conclusions

Reports suggest an association between AI manifestations and MDS, including: acute systemic vasculitis; chronic AI syndromes; autoimmune skeletal disorders; immune-mediated cytopenias; and serological abnormalities. 3,13 21 Inflammatory syndromes may precede or follow the diagnosis of MDS. 3,10,22 Cytokines implicated in MDS include tumor necrosis factor alpha (TNF-α) and transforming growth factor beta (TGF-β), which result in upregulation of proinflammatory and myelosuppressive cytokines, respectively. 23,24 Interferon regulatory factor-1 (IRF-1) is involved in activities including inflammatory responses, and IRF mRNA was increased in MDS patients with AIM. 19 Immune cells that may be involved in AIM include natural killer (NK) cells and regulatory T-cells. 25,26 The prognostic impact of AIM in MDS is a matter of debate. In one study, the median survival of MDS patients with no AIM was 25 months compared to 9 months in patients with AIM. 3 Acute vasculitis had a particularly poor prognosis, with a median survival of only 6 months. However, this study did not take into account the IPSS score. In another study that considered IPSS score and treatment, patients with AIM (n=13) did not have an inferior prognosis to those without (n=57). 30 We separated our patients into lower IPSS risk, and higher risk receiving azacitidine, and compared the outcomes of those with and without AIM. In both instances we did not find a significant difference in OS between groups, though small numbers limits interpretation of these analyses. Supportive treatment of AIM in MDS requires careful consideration, as immunosuppressive medications (ISM) may increase infectious risk and exacerbate cytopenias. In one study, however, 26 of 27 of MDS patients with AIM responded favorably to ISM but only 6 experienced sustained AIM remission. 23 There are reports of MDS progression with immunosuppression, 26 but on the other hand, immunosuppressive therapy such as anti-thymocyte globulin (ATG) and cyclosporine may result in responses in some MDS patients. 7 Given the uncertain safety of ISM for the treatment of AIM in MDS, these medications should be used with caution and patients monitored closely.

Treatment of MDS may improve AIM. In one series of 22 patients with AIM receiving azacitidine for MDS, 19 (86%) had an AIM response within 3-6 azacitidine cycles, allowing discontinuation of ISM. 29 Azacitidine is thought to act in this regard by increasing the number of FOXP3+ regulatory T-cells and inhibiting CD4+ T-cells. 3,30

In six patients with AIM in MDS relapsed or refractory to steroid treatment, 5 had a response to lenalidomide, with 3 complete remissions. 31 There are reports, however, implicating lenalidomide in increased AIM. 32 Lenalidomide modulates the function of NK cells, monocytes, dendritic cells, and T-cells, and increases cytokines involved in attenuating inflammatory responses. 25,26

The findings in our patients are consistent with other reports, with AIM occurring concomitantly with MDS diagnosis in 4.4%, in patients with a median age of 68 years, 9 of 11 having adverse karyotype, and present in all IPSS risk groups. 9,11,13,33 Though this percentage is lower than in previous reports, we restricted the analysis to patients presenting with AIM around the time of MDS diagnosis and excluded patients with longstanding autoimmune disorders.

In conclusion, MDS should remain on the differential diagnosis of patients undergoing workup for AIM. Similarly, MDS patients with AIM should be identified as symptoms may respond to therapy with immunosuppressive medications or specific MDS treatments.
References

1. Ades L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet 2014;383:2239-52.

2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.

3. Will B, Zhou L, Vogler TO, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 2012;120:2076-86.

4. Gadjii M, Adebayo Awe J, et al. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. Clin Cancer Res 2012;18:3293-304.

5. Rhysen GW, Starczynowski DT. Deregulation of microRNAs in myelodysplastic syndrome. Leukemia 2012;26:13-22.

6. del Rey M, O’Hagan K, Dellett M, et al. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes. Leukemia 2013;27:610-18.

7. Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008;26:2505-11.

8. Zeng W, Miyazato A, Chen G, et al. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood 2006;107:167-75.

9. Enright H, Jacob HS, Vercellotti G, et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 1995;91:403-8.

10. Giannouli S, Voulgarelis M, Zintzaras E, et al. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) 2004;43:626-32.

11. de Holland A, Beucher A, Henrion D, et al. Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res (Hoboken) 2011;63:1188-94.

12. Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009;100:822-8.

13. Frietsch JJ, Dornaus S, Neumann T, et al. Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review. Eur J Haematol 2014;93:247-59.

14. Bouali F, Berrah A, Si Ahmed-Bouali D, et al. [Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients)]. Rev Med Interne 2005;26:777-83. [Article in French].

15. Mekinian A, Braun T, Decaux O, et al. Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases. Medicine (Baltimore) 2014;93:1-10.

16. Castro M, Conn DL, Su WP, Garton JP. Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 1991;18:721-7.

17. Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996;33:150-62.

18. Ramakrishna R, Chaudhuri K, Sturgess A, Manoharan A. Haematological manifestations of primary Sjogren’s syndrome: a clinicopathological study. Q J Med 1992;83:547-54.

19. Hebbar M, Brouillard M, Wattel E, et al. Association of myelodysplastic syndrome and relapsing polyarthritis: further evidence. Leukemia 1995;9:731-3.

20. Sokol RJ, Hewitt S, Booker DJ. Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes. J Clin Pathol 1989;42:1088-91.

21. Okamoto T, Okada M, Mori A, et al. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 1997;66:345-51.

22. Ahn JK, Cha HS, Koh EM, et al. Behçet’s disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology (Oxford) 2008;47:1228-30.

23. Stirewalt DL, Mhyre AJ, Marcondes M, et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol 2008;140:444-53.

24. Zhou L, Nguyen AN, Sohal D, et al. Inhibition of the TGF-beta receptor 1 kinase promotes hematopoiesis in MDS. Blood 2008;112:2434-43.

25. McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol 2012;2012:513702.

26. Castelli R, Cassin R, Cannavo A, Cugno M. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 2013;13:1-7.

27. Enright H, Miller W. Autoimmune phenomena in patients with myelodysplastic syndromes. Leuk Lymphoma 1997;24:483-9.

28. Kwong YL, Au WY, Liang RH. Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: association with -7/Tq. Cancer Genet Cytogenet 1998;15:104-97.

29. Fraise JB, Mekinian A, Grignano E, et al. Efficacy of azacitidine (AZA) in autoimmune and inflammatory disorders (AID) associated with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Blood 2015;126:1955.

30. Aggarwal S, van de Loosdrecht AA, Alhan C, et al. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 2011;153:568-81.

31. Takeoka Y, Miura A, Nakamura K, et al. A detailed analysis of myelodysplastic syndrome complicated by autoimmune or inflammatory disorders: a possible efficacy of low-dose lenalidomide. Blood 2014;124:3256.

32. Montefusco V, Galli M, Spina F, et al. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. Leuk Lymphoma 2014;1:6-8.

33. Mekinian A, Grignano E, Braun T, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford) 2016;55:291-300.